Synthesis and Bioactivity of a Brasilicardin A Analogue Featuring a Simplified Core

Org Lett. 2015 Jul 17;17(14):3608-11. doi: 10.1021/acs.orglett.5b01712. Epub 2015 Jul 6.

Abstract

An analogue 2 of Brasilicardin A, 1 (BraA), a potent immunosuppressive and cytotoxic agent, was synthesized in which the natural tricyclic skeleton was replaced with a synthetically more accessible substituted tetrahydronaphthalene core. BraA, this analogue (BraL), and cyclosporine A were tested for their ability to inhibit the proliferation of human T cells upon CD3/CD28 activation. Although BraL did not impact T cell activation over the dose range tested, this study shows the inhibitory activity of BraA on human T cells for the first time.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / chemical synthesis*
  • Aminoglycosides / chemistry
  • Aminoglycosides / pharmacology*
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • CD28 Antigens
  • CD3 Complex
  • Cyclosporine / chemistry*
  • Humans
  • Immunosuppressive Agents / chemistry
  • Immunosuppressive Agents / pharmacology*
  • Molecular Structure
  • Naphthalenes / chemistry*
  • T-Lymphocytes / drug effects*

Substances

  • Aminoglycosides
  • Antineoplastic Agents
  • CD28 Antigens
  • CD3 Complex
  • Immunosuppressive Agents
  • Naphthalenes
  • brasilicardin A
  • Cyclosporine